Esco Lifesciences Group

A History of Excellence

The Esco Lifesciences Group is committed to innovation and excellence. We have a proven track record, with more than four decades of developing, producing, and servicing world class life sciences tools and technologies.

OUR VISION

The Esco Lifesciences Group aims to invent, discover, and commercialize enabling technologies to make human lives healthier and safer.

 

OUR MISSION

Innovation

Embrace innovation and take calculated risks in order to address unmet needs

Effective Operations

Utilize the Esco Business System as a strategic tool to continuously improve our operating effectiveness

Global Footprint

Deepen our global footprint and market access

Transformation

Transform our product and service offerings, and increase the share of our recurring revenues

Life Sciences Ecosystem

Build a leading life sciences ecosystem; operating across life sciences tools, medical technology, CDMO services for cell and gene therapy, and selected healthcare services.

Taking the Lead

Be a leading life sciences company with deep and localized operations in China, Southeast Asia, Europe, and North America.

Social Responsibility

Benefit the communities that we operate in

Milestones

Esco Lifesciences Group

1978 - 1997

Pioneering Cleanroom Technology in Southeast Asia

Esco Lifesciences Group
Esco Lifesciences Group

Esco was founded in 1978 by Singaporean pharmacists Lim Lay Yew and Low Yae Foong. Esco was launched to manufacture cleanroom products for Singapore’s then-booming electronics industry. In its early days, Esco manufactured its first laminar flow clean bench. During this time, Esco also designed and built its first microelectronics class 10,000 cleanroom for Siemens Corporation. The business expanded as Esco embarked on distribution to the pharmaceutical, life science, biotechnology, and medical research markets in Malaysia and Indonesia with the establishment of Esco Micro (M) Sdn Bhd and PT Esco Bintan Indonesia.

2000 - 2005

Transformation into a Life Sciences Tools Company

Esco Lifesciences Group

In 2000, Esco successfully adapted to the field shifting towards the life sciences. The company quickly transformed itself and earned a reputation for producing and providing laboratory and biological safety equipment. Esco became the first Asian manufacturer to earn EN 12469 certification for biological safety cabinets in 2001 and achieved its first NSF/ANSI certification in 2004. In 2005, Esco was invited by the Chinese Food and Drug Administration to participate in a joint committee to develop the National Standard for Biological Safety Cabinets.

2006 - 2008

Expansion of Operations

Esco Lifesciences Group

To expand the sales of its biological safety cabinets to the global market, Escos set up operations in the United States with the establishment of Esco Technologies, Inc. as an integrated sales, marketing, and distribution center. Offices were also set up in China, Northern America, the Middle East, and Africa. This was followed by a global marketing program (Esco. World Class. Worldwide) to establish its presence as a global life sciences tools company. In 2007, annualized production exceeded 10,000 units.

2009

Esco launches its Pharma Division

Esco Lifesciences Group

Following the success of its biological safety cabinets, Esco established Esco Pharma to expand its repertoire of life sciences tools to include Isotherm® ovens and incubators, Pharmacon™ downflow booths, Swift® MaxPro and MiniPro new-generation PCR thermal cyclers, Labculture® In Vitro Fertilization Workstations, the CelCulture® range of carbon dioxide incubators, and the Lexicon® range of Ultra-low Temperature Freezers.

2012

Esco launches its Medical Division

Esco launched the Esco Medical Division to offer world-class ART/IVF solutions worldwide, with a focus on the new MIRI® Multi-room Incubator. As the IVF MedTech business unit of the Esco Group, Esco Medical provides innovative solutions to fertility clinics and laboratories.

2013 - 2014

New generation life sciences tools

Esco Lifesciences Group
Esco Lifesciences Group

By applying innovative technologies, Esco launched a new range of life sciences tools which include the Airstream® G3 Class II (the greenest low noise biological safety cabinet in the world), the eSafe®  BSC (technologically and ergonomically advanced TUV-NORD certified BSC), the MIRI® GA gas and temperature validation unit, the Multi-zone ART Workstation, and the MIRI® Time-Lapse incubator.

2015 - 2018

Esco ventures into Medtech and Biotechnology

In 2016, Esco Healthcare was launched as an umbrella for Esco Pharma, Esco VacciXcell, and Esco TaPestle Rx. The technologies developed from Esco Healthcare were cumulated to establish Esco Aster, the bioprocessing division of the Esco Group of Companies that provides biomanufacturing of vaccines and biologics.
 

Esco has also invested RMB 100 million into a new 20,000m² Innovation Center in Taicang, China while, at the same time, setting up a venture office in Esco Beijing. Throughout the years, Esco has been given the Singapore Prestige Brand Award for 3 consecutive years and the Top Employer Brand Award, which is a testament to its commitment to its core values and its mission to improve lives through science.

2020 - 2021

Aiding in COVID-19 relief efforts & Esco 3.0

​Amidst the COVID-19 pandemic, Esco continues to support our customers with an undisrupted supply of products and services. Thousands of biosafety cabinets, PCR cabinets, freezers, and other COVID-related equipment were installed and serviced by Esco across the globe. The Trace, Test, and Treat Platform was also launched to help with the worldwide COVID pandemic relief.

As a leading provider of life sciences tools & services, Esco is poised to benefit from the sustained growth of the healthcare and biopharma industries in Asia and globally. In 2021, we embarked on our Esco 3.0 transformation, which primarily involves strategic bolt-on M&A and expedited expansion in China, our priority market, to maintain the strong revenue growth we have achieved over the last decade. We will also increase our R&D and in-licensing efforts to develop and commercialize enabling novel life science research tools in emerging domains, thus enabling fundamental scientific discoveries and, ultimately, the diagnostics and medicines of tomorrow.